This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stocks in play: Satellos Bioscience Inc.
Has completed a consolidation of its outstanding common shares on the basis of one post-consolidation Common Share for every 12 pre-consolidation Common Shares. The Company believes that the Consolidation should permit it to qualify for a potential listing on The NASDAQ Stock Market LLC. Satellos Bioscience Inc. shares T.MSCL are trading down $0.12 at $1.22.
